Non small cell lung cancer future or investigational therapies
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]
Overview
Overview
The KEYNOTE-024 trial used pembrolizumab (a monoclonal antibody against programmed death 1) in patients with advanced non-small cell lung cancer and PD-L1 expression. Pembrolizumab was associated with significantly longer progression-free and overall survival. The reported adverse events were lower than those of platinum-based chemotherapy. [1]
Future or Investigational Therapies
Future or Investigational Therapies
KEYNOTE-024 trial
- Phase III, open-label, randomized clinical trial[2]
- Patients with untreated, advanced non-small cell lung cancer and PD-L1 expression[2]
- Pembrolizumab was associated with:[2]
- Significantly longer progression-free (10.3 months) and overall survival at 6 months (80.2%)
- Low adverse events compared to platinum-based chemotherapy
References
References
- ↑ Martin Reck, M.D. et al. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer. New England Journal of Medicine. October 9 2016 DOI: 10.1056/NEJMoa1606774 http://www.nejm.org/doi/full/10.1056/NEJMoa1606774
- ↑ 2.0 2.1 2.2 Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY; et al. (2016). “Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial”. Lancet. 387 (10027): 1540–50. doi:10.1016/S0140-6736(15)01281-7. PMID 26712084.
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH